Get the Stockscreener App
1.0361
3.50%
0.0361
Citius Oncology Inc stock is traded at $1.0361, with a volume of 94,896.
It is up +3.50% in the last 24 hours and down -20.38% over the past month.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
See More
Previous Close:
$1.00
Open:
$1
24h Volume:
94,896
Relative Volume:
0.21
Market Cap:
$87.77M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.41%
1M Performance:
-20.38%
6M Performance:
-80.17%
1Y Performance:
-13.03%
1-Day Range:
$1.00
$1.04
1-Week Range:
$0.95
$1.10
52-Week Range:
$0.5506
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.035 | 84.80M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
125.38 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.00 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.50 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.12 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Earnings Miss: Will Citius Oncology Inc stock sustain high P E ratiosJuly 2025 Institutional & Verified Technical Signals - moha.gov.vn
Citius Oncology, Inc. (NASDAQ:CTOR) Sees Significant Increase in Short Interest - Defense World
Citius Oncology, Inc. (NASDAQ:CTOR) Short Interest Update - MarketBeat
Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga France
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption - TipRanks
Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why - Benzinga
Citius Oncology, Inc. Full Year Loss Increases - Nasdaq
Citius Oncology Transitions to Commercial Stage: Analyzing the 10-K Filing and the 2026 Outlook for LYMPHIR - FinancialContent
Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results - MarketBeat
Citius Oncology Fiscal 2025 Loss Widens - marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - WV News
Citius Pharmaceuticals, Inc. SEC 10-K Report - TradingView — Track All Markets
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025 - marketscreener.com
Citius Oncology raises $18M through direct offering - MSN
Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
Is Citius Oncology Inc a good long term investmentFibonacci Extensions & Free Superior Trading Gains - earlytimes.in
Citius Oncology Earnings Notes - Trefis
Citius Oncology, Inc.(NasdaqCM: CTOR) added to Russell 3000E Value Index - marketscreener.com
Citius Oncology (CTOR) Price Target Increased by 100.00% to 6.12 - MSN
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Raises $18M Through Direct Offering - TipRanks
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com
Citius Oncology (NASDAQ:CTOR) Shares Up 6.4%What's Next? - MarketBeat
Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada
Citius Oncology, Inc. announced that it has received $16.6 million in funding - marketscreener.com
Citius Oncology (NASDAQ: CTOR) raises $1.4M, adds large warrant package - Stock Titan
Citius Oncology added to the Russell Microcap Index - MSN
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology raises $18 million to support cancer therapy launch - Investing.com
Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com Nigeria
Citius Oncology stock tumbles after $18M capital raise - Investing.com India
Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com
Press Release: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - 富途牛牛
Citius Oncology, Inc. announced that it expects to receive $16.6 million in funding - marketscreener.com
What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in
Citius Oncology Launches Lymphir In US For Skin Cancer - MSN
Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria
Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com India
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com
Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView — Track All Markets
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times
What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.43%
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):